

Understanding the Emerging Role of I-O in GI Cancers

Friday, 27 September 2019 | 18:00–20:00

Pamplona Auditorium, Hall 2

Fira Gran Via

Barcelona, Spain



I-O Studies in CRC: Patient Populations of Today and Tomorrow

Miriam Koopman, MD

Professor, Department of Medical Oncology

UMC Utrecht

Utrecht, Netherlands



Evolving Treatment Options and the Potential of I-O for Patients With HCC

Robin Kate Kelley, MD

Associate Professor of Clinical Medicine, Division of Hematology/Oncology

Helen Diller Family Comprehensive Cancer Center, University of California

San Francisco, United States



From Trials to Practice: The Possible Future of I-O in Gastric/GEJ Cancer

Kohei Shitara, MD

Chief of Department of Gastroenterology and Gastrointestinal Oncology

National Cancer Center Hospital East

Kashiwa, Japan



Clinical Data With I-O in Esophageal Cancer

Ian Chau, MD

Medical Oncologist, Gastrointestinal and Lymphoma Units

Royal Marsden Hospital (London and Surrey)

London, United Kingdom

Meeting Chair

CRC=colorectal cancer; GEJ=gastroesophageal junction; GI=gastrointestinal; I-O=immuno-oncology.

This Industry-Sponsored Symposium Is a Medical Education Activity That Is Organized and Funded by the Medical Department of Bristol-Myers Squibb.